<lvz class="bqmfja"></lvz>

巅峰国际

Be the most trusted biotech company

2018-11-29

Henlius Completed Data Analysis of the Phase 1 Study for Its HLX03
2018-11-26

Henlius HLX22 Received IND Application Acceptance Notification from NMPA
2018-11-16

Henlius Successfully Held Its Second Scientific Advisory Board (SAB) Meeting in California
2018-11-01

Cooperation Upgrades! Henlius Has been Granted to Develop and Commercialize AC101 in the World
2018-10-26

New Progress! Henlius Received Clinical Approval for Its Anti-VEGFR2 Monoclonal Antibody, HLX12
2018-10-18

Henlius Nominated for the Global Generics & Biosimilars Awards 2018 in Two Categories
2018-09-10

Important News! Henlius Combination Therapy Received Approval to Conduct Clinical Trials in China
2018-08-09

Henlius Submitted Investigational New Drug Application for Its HLX12
2018-06-21

Henlius and Accord Entered into an License Agreement for HLX02

1
2